Quizzes

Quiz

Progression-Free Survival Outcomes With Pegylated Liposomal Doxorubicin in Patients With Desmoid Tumors

06/19/2026

What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?

What was the effect of pegylated...

06/19/2026

Oncology

Quiz

Tiragolumab Plus Atezolizumab and Chemotherapy in ES-SCLC

06/19/2026

According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?

According to exploratory...

06/19/2026

Oncology

Quiz

Safety and Preliminary Activity of Eganelisib in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

06/19/2026

According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...

According to results from a...

06/19/2026

Oncology

Quiz

Polycythemia Vera Management Pre-Survey

06/17/2026

Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice.

Thank you for taking part in...

06/17/2026

Oncology

Quiz

Pivekimab Sunirine for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasms

06/09/2026

Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?

Which finding from the CADENZA...

06/09/2026

Oncology

Quiz

Durvalumab Plus BCG for BCG-Naïve Patients With Non-Muscle Invasive Bladder Cancer

06/08/2026

Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?

Which key finding from the phase...

06/08/2026

Oncology

White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey

Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey

White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey

PV Management Question 4

05/21/2026

Lucia Masarova, MD

Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.

Test your understanding of the...

05/21/2026

Oncology

White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey

PV Management Question 3

05/21/2026

Lucia Masarova, MD

Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.

Learn how persistent...

05/21/2026

Oncology

Recent News

News

Durvalumab Plus Anlotinib Maintenance Improves PFS in Extensive-Stage Small Cell Lung Cancer

07/02/2026

Emily Estrada

Maintenance therapy with durvalumab plus anlotinib improved progression-free survival compared with durvalumab alone in patients with extensive-stage small cell lung cancer following first-line chemoimmunotherapy, according to results from...

Maintenance therapy with...

07/02/2026

Oncology

News

Serplulimab Plus Chemotherapy Shows Sustained Survival Benefit in Extensive-Stage Small Cell Lung Cancer

07/02/2026

Emily Estrada

Updated findings from the ASTRUM-005 trial showed that adding serplulimab to carboplatin and etoposide continued to improve long-term survival in patients with previously untreated extensive-stage small cell lung cancer.

Updated findings from the...

07/02/2026

Oncology

News

Real-World Study Confirms Survival Benefit of First-Line Chemoimmunotherapy in Extensive-Stage Small Cell Lung Cancer

07/02/2026

Emily Estrada

Real-world data from a large retrospective cohort study demonstrated that first-line chemoimmunotherapy significantly improved survival in patients with extensive-stage small cell lung cancer.

Real-world data from a large...

07/02/2026

Oncology

FDA Approval

FDA Approves BESREMi Pen, Expanding Self-Administration Options for Patients With Polycythemia Vera

07/01/2026

Emily Estrada

The FDA has approved the BESREMi Pen, a prefilled ropeginterferon alfa-2b-njft delivery device, for adults with polycythemia vera, providing a new option designed to simplify self-administration of chronic interferon therapy.

The FDA has approved the BESREMi...

07/01/2026

Oncology

News

MRI-Guided Adaptive Radiotherapy Enables Margin Reduction in Adult Patients With Glioblastoma

06/30/2026

Emily Estrada

Results from the phase 2 UNITED trial demonstrated that MRI-guided adaptive radiotherapy with reduced treatment margins was associated with a low rate of marginal failure in adult patients with glioblastoma.

Results from the phase 2 UNITED...

06/30/2026

Oncology

News

WT1 Peptide Vaccine Demonstrates Immune Activity in Pediatric High-Grade Gliomas

06/30/2026

Emily Estrada

Results from a phase 1/2 study demonstrated that a Wilms' tumor gene 1 (WT1) peptide vaccine is well tolerated and elicited immune responses associated with improved survival among pediatric patients with high-grade gliomas.

Results from a phase 1/2 study...

06/30/2026

Oncology

News

Venetoclax-Based Conditioning Regimen Prior to Allo-HSCT for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

06/30/2026

Emily Estrada

Results from a phase 2 trial demonstrated that incorporating venetoclax into a fludarabine and melphalan conditioning regimen before allogeneic hematopoietic stem cell transplantation showed encouraging clinical promise in older patients with...

Results from a phase 2 trial...

06/30/2026

Oncology

News

Navitoclax Plus Venetoclax and Decitabine Shows Early Activity in High-Risk Myeloid Malignancies

06/30/2026

Emily Estrada

Results from a phase 1 study demonstrated that the addition of navitoclax to venetoclax plus decitabine was safe and showed encouraging preliminary activity among patients with high-risk myeloid malignancies.

Results from a phase 1 study...

06/30/2026

Oncology

News

Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma

06/26/2026

Emily Estrada

According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.

According to results from an...

06/26/2026

Oncology

News

Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas

06/25/2026

Stephanie Holland

Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.

Long-term follow-up of patients...

06/25/2026

Oncology